HO-3867 showed more clinically relevant IC50 values as compared to APR-246, and synergistic effects were observed when combined with the PARP inhibitor olaparib in vitro and in vivo in a xenograft model of advanced ovarian cancer with mutant p53. This evidence concerns the gene TP53 and ovarian cancer.